慢加急性肝衰竭3级患者14天等待名单死亡率高于Status-1a患者
该研究基于美国器官共享网络2002至2014年数据,比较了3377例Status-1a与5099例慢加急性肝衰竭3级(ACLF-3)等待肝移植患者的短期等待名单死亡率。结果显示,ACLF-3患者14天死亡率显著高于Status-1a患者(亚风险比1.45,95%CI 1.31-1.61),且独立于MELD-Na评分。
要点
- ACLF-3患者7天、14天、21天死亡率分别为18.0%、27.7%、32.7%,呈上升趋势(P < 0.001)。
- Status-1a患者7天、14天、21天死亡率分别为17.9%、19.3%、19.8%,趋势平稳(P = 0.709)。
- ACLF-3患者14天死亡率高于Status-1a患者(亚风险比1.45,95%CI 1.31-1.61),独立于MELD-Na评分。
核心结论
- ACLF-3患者在列入等待名单时14天死亡率高于Status-1a患者,且独立于MELD-Na评分;这些发现说明早期移植评估和考虑ACLF-3患者移植优先性的重要性。
研究设计与样本
- 基于美国器官共享网络(United Network for Organ Sharing)数据库2002至2014年数据的分析,纳入3377例Status-1a患者和5099例ACLF-3患者,ACLF依据欧洲肝病研究学会慢性肝衰竭联盟标准识别,采用竞争风险回归评估等待名单死亡风险。
主要发现
- ACLF-3患者7天死亡率18.0%、14天27.7%、21天32.7%,呈上升趋势(P < 0.001)。
- Status-1a患者7天死亡率17.9%、14天19.3%、21天19.8%,趋势平稳(P = 0.709)。
- 校正MELD-Na分类后,ACLF-3患者14天内死亡风险显著高于Status-1a患者(亚风险比1.45;95%CI 1.31-1.61)。
- MELD-Na分类与ACLF-3的交互作用分析显示,在全部三个MELD-Na分类中,ACLF-3患者14天死亡风险均高于Status-1a患者。
关键数值与推荐
- MELD-Na评分按分类变量处理,分为<36、36-40和>40三个类别。
临床怎么用
- 作者认为,这些发现说明早期移植评估和考虑ACLF-3患者移植优先性的重要性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Patients listed for liver transplantation (LT) as status 1a currently receive the highest priority on the waiting list. The presence of acute on chronic liver failure (ACLF) with three or more organs failing (ACLF-3) portends low survival without transplantation, which may not be reflected by the Model for End-Stage Liver Disease-Sodium (MELD-Na) score. We compared short-term waitlist mortality for patients listed status 1a and those with ACLF-3 at listing. Data were analyzed from the United Network for Organ Sharing database, years 2002-2014, for 3,377 patients listed status 1a and 5,099 patients with ACLF-3. Candidates with ACLF were identified based on the European Association for the Study of the Liver Chronic Liver Failure Consortium criteria. MELD-Na score was treated as a categorical variable of scores <36, 36-40, and >40. We used competing risks regression to assess waitlist mortality risk. Evaluation of outcomes through 21 days after listing demonstrated a rising trend in mortality among ACLF-3 patients at 7 days (18.0%), 14 days (27.7%), and 21 days (32.7%) (P < 0.001) compared to a stable trend in mortality among individuals listed as status 1a at 7 days (17.9%), 14 days (19.3%), and 21 days (19.8%) (P = 0.709). Multivariable modeling with adjustment for MELD-Na category revealed that patients with ACLF-3 had significantly greater mortality (subhazard ratio, 1.45; 95% confidence interval, 1.31-1.61) within 14 days of listing compared to status-1a candidates. Analysis of the interaction between MELD-Na category and ACLF-3 showed that patients with ACLF-3 had greater risk of 14-day mortality than status-1a-listed patients, across all three MELD-Na categories. Conclusion: Patients with ACLF-3 at the time of listing have greater 14-day mortality than those listed as status 1a, independent of MELD-Na score; these findings illustrate the importance of early transplant evaluation and consideration of transplant priority for patients with ACLF-3.
引用
- Sundaram V, Shah P, Wong RJ, et al. Patients With Acute on Chronic Liver Failure Grade 3 Have Greater 14-Day Waitlist Mortality Than Status-1a Patients. Hepatology. 2019. PMID: 30908660. doi:10.1002/hep.30624
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。